store at low temperature
store at -20°C
Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 428.00 | |
5 mg | In stock | $ 1,370.00 | |
10 mg | In stock | $ 1,850.00 | |
25 mg | In stock | $ 2,730.00 | |
50 mg | In stock | $ 3,680.00 | |
100 mg | In stock | $ 4,900.00 |
Description | Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma. |
In vitro | In an E/T ratio-dependent manner, tafasitamab (XmAb5574) induced cytotoxicity to Mino and Jeko (MCL) cell lines. It also increased antibody-dependent cellular phagocytosis (ADCP) and antiproliferative activity. Additionally, tafasitamab (XmAb5574) can enhance the anti-proliferative activity induced by caspase-mediated apoptosis[1][2]. |
In vivo | In a xenograft tumor model of disseminated BL mice, tafasitamab (2.5 μg/kg, once on day 1) inhibited lymphoma growth[1]. |
Synonyms | MOR00208, XmAb5574, Tafasitamab-cxix |
Molecular Weight | N/A |
CAS No. | 1422527-84-1 |
store at low temperature
store at -20°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tafasitamab 1422527-84-1 Apoptosis Immunology/Inflammation Immunology/Inflammation related MOR 00208 MOR-00208 MOR00208 XmAb5574 Tafasitamab-cxix inhibitor inhibit